Viking Therapeutics ( (VKTX) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Viking Therapeutics’ stock has experienced a notable decline despite the company announcing positive Phase 2 results for its lead obesity program, VK2735, which demonstrated significant weight reduction. The company’s strong financial position supports ongoing Phase 3 trials and further development of its clinical programs. Analysts remain optimistic, maintaining a strong buy consensus due to the company’s strategic positioning and potential growth in the metabolic disease market.
More about Viking Therapeutics
YTD Price Performance: -19.80%
Average Trading Volume: 6,488,771
Technical Sentiment Signal: Buy
Current Market Cap: $3.8B
For further insights into VKTX stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.